Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.
Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.
Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.
Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.
With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.
To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.
Centogene N.V. (Nasdaq: CNTG) reported unaudited financial results for Q2 and H1 2022, showing a 21.6% increase in revenues to €11.2 million. The Diagnostics segment saw an 18.3% rise to €7.5 million, while the Pharma segment increased 29% to €3.7 million. Despite a net loss of €11.9 million in Q2, the loss improved by 11.9% YoY. Total revenues for H1 were €21.4 million, up 12.6%. The company anticipates 2022 revenue growth between 9% to 13%, reaching €46.5 to €48.2 million.
Centogene N.V. (Nasdaq: CNTG) has been notified by Nasdaq that it has not met the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has until June 12, 2023, to regain compliance, during which its shares will continue to trade on Nasdaq. If the bid price closes at or above $1.00 for 10 consecutive days before this deadline, the compliance issue will be resolved. The company is evaluating options to address this deficiency but remains committed to its mission in the rare and neurodegenerative diseases sector.
Centogene N.V. (Nasdaq: CNTG) announces its conference schedule for December 2022, highlighting participation in the 4th Annual Gene Therapy for Neurological Disorders Meeting from December 5-8 in Boston and the 67th Annual Meeting of the Japan Society of Human Genetics from December 14-17 in Yokohama. The company invites attendees to schedule one-on-one meetings with its Pharma and CRO business development team. Centogene focuses on life science solutions for rare and neurodegenerative diseases, leveraging its Biodatabank for enhanced diagnostics and drug discovery.
Centogene N.V. (Nasdaq: CNTG) announced its conference schedule for November 2022, highlighting participation in events in the U.S. and Spain to foster collaboration in rare and neurodegenerative diseases. Key events include the World Orphan Drug Congress (WODC) Europe from November 14-17, 2022 in Barcelona, and the NSGC Annual Conference from November 16-20, 2022 in Nashville, TN. Centogene invites attendees to arrange one-on-one meetings, aiming to enhance partnerships and dialogue in precision medicine.
Centogene N.V. (Nasdaq: CNTG) has launched its Biodata Network, a suite of data-driven solutions aimed at enhancing drug discovery for rare and neurodegenerative diseases. The company partnered with BC Platforms to provide access to a comprehensive dataset, featuring 80,000 genetic sequences and expanding the genomic data available by 20%. This initiative supports biopharma companies with customized Biodata Licenses and Insight Reports, aiming to accelerate therapeutic development. Centogene's Biodatabank comprises nearly 700,000 patients from over 120 countries, emphasizing patient privacy and compliance with regulations.
Centogene N.V. (Nasdaq: CNTG) has announced its participation in two major events in October 2022, focusing on rare and neurodegenerative diseases. The company will attend the ESGCT Annual Congress in Edinburgh from October 11-14, 2022, offering one-on-one meetings. Following that, it will participate in BIO-Europe in Leipzig from October 24-26, 2022, featuring a digital presentation by CEO Kim Stratton. Partners are encouraged to schedule meetings to explore collaborations.
Centogene N.V. (Nasdaq: CNTG) has achieved a significant milestone in the Rostock International Parkinson's Disease (ROPAD) Study, enrolling and genetically testing 12,500 participants globally. This study is the largest of its kind, aiming to understand genetics in Parkinson's disease (PD) through over 120 study sites worldwide. The company collaborates with Denali Therapeutics to develop a first-in-class Parkinson’s Disease Panel, screening for mutations in the LRRK2 gene. Participants with these mutations may qualify for future clinical studies to explore new therapeutic avenues for PD.
Centogene N.V. (Nasdaq: CNTG) has announced its September 2022 investment and partnering conference schedule. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York on September 12, 2022, and at the 9th Annual HealthTech Investment Forum in Basel on September 20, 2022. CEO Kim Stratton will lead the presentations, inviting investors for one-on-one meetings. Centogene is recognized for its comprehensive biodata services aimed at rare and neurodegenerative diseases, leveraging a vast network of physicians and a significant biodatabank.
Centogene N.V. (Nasdaq: CNTG) reported Q1 2022 revenues of €10.3 million, a 3% increase from €10.0 million in Q1 2021. The Diagnostics segment grew by 11% to €7.1 million, driven by Whole Exome and Genome Sequencing. The Pharma segment, however, saw a 10% decline to €3.2 million. The phased-out COVID-19 Testing Business generated €19.5 million, down from €55.0 million in Q1 2021. Despite a net loss of €6.4 million, the company maintains its FY 2022 revenue growth guidance of 15-20%, targeting €50-52 million. Notable collaborations were established with Agios and Takeda.
Centogene N.V. (Nasdaq: CNTG) held its Annual General Meeting on June 27, 2022, where shareholders approved all proposals, including the appointment of Miguel Coego Rios as Managing Director and CFO. Shareholders adopted the Dutch statutory annual accounts for 2021 and discharged Management and Supervisory Boards from liability. With 56.4% of issued share capital represented, the meeting emphasized the company's commitment to addressing rare diseases and the potential for future growth.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is CentoMD®?
Which segments does Centogene operate in?
What regions does Centogene serve?
Who are Centogene’s main partners?
What are some recent achievements of Centogene?
How does Centogene contribute to drug discovery?
What research certifications does Centogene hold?
How extensive is Centogene's physician network?
Where can I learn more about Centogene?
